Record Revenue Growth
Q4 revenue reached $6.3 million, marking a 48% increase from the previous year. Annual revenue was $25.4 million, reflecting a 40% growth, with antigens up 44% and QAPs up 38%.
Strong Financial Performance
The company reported a 55% margin for Q4 and an 18% EBITDA. On an annual basis, margins increased to 53% from 40% last year.
Strategic Investments and Share Repurchases
Over $2 million was invested in facilities and equipment, and 2.6 million shares were repurchased, stabilizing the share price.
Operational Excellence and Capacity Building
New facilities and a lab were opened, supported by federal and provincial grants, and an electronic quality management system was implemented.
Kinlytic Progress
Recognition of $3 million in Kinlytic milestone payments contributed to the fiscal year performance. The project is on track for 2027.